[Funding alert] Biotech Company BioThrust Secures Funding

In order to meet approved therapeutic standards, the majority of stem cell manufacture is done in small batches, which makes it expensive and difficult to expand.

Read also - London-based OpenDialog Secures over €7 Million in Series A Round Funding

The bionic bioreactors from BioThrust are made to be more scalable and have lower development costs for stem cells. The application of stem cell therapists is widespread in the treatment of diseases like Parkinson's disease, cancer, and spinal cord injury.

According to Patrick Bongartz, CEO of BioThrust: "Our goal is to provide a universal cell multiplication platform in which we achieve high concentrations of therapeutically active cells. This is a system that can be used from the fundamental development in the university clinic to the industrial producer."

Frank Thelen, CEO of Freigeist Capital, shared: "BioThrust has the potential to give millions of people access to revolutionary stem cell therapies. We look forward to supporting the RWTH Aachen team with our experience in building up a globally relevant BioTech company."

In the next months, the company hopes to use the funds to expand its workforce and identify suitable partners for test projects.

Read also - Berlin-based Packmatic Secures €15 Million in Series A Round Funding

About BioThrust

They are a German biotech firm called BioThrust, and they were bringing industrial-scale cell production to life. With the help of the artificial lung in their bionic bioreactor, they can cultivate cells in a stress-free environment and increase their quality and concentration. They deliver bubble-free gas exchange for the process using a special, patent-pending membrane architecture.

Read also - London-based Metris Energy Secures €2.3 Million in Pre-Seed Funding